Systemic Lupus Erythematosus |
Sle |
Clinical Trial: Role of altered CD40-Ligand gene transcription in systemic lupus erythematosus
This study is currently recruiting patients.
|
Purpose
Systemic lupus erythematosus is an often devastating autoimmune disease which affects 1 in 2,000 women in the United States. Recently, several research laboratories have reported that a protein, named CD40-ligand (CD154), is overexpressed by a subset of white blood cells, called lymphocytes, in patients with lupus. Expression of CD154 appears critical to the generation of antibodies that cause disease in lupus. Blocking CD154 interactions in the immune system has been shown to decrease disease activity in animal models of lupus. We propose to study the regulation of CD154 in patients with lupus in hopes of inhibiting its abnormal and deleterious expression.
| Condition |
|---|
| Lupus Erythematosus, Systemic |
MedlinePlus related topics: Lupus
Study Type: Observational
Study Design: Natural History, Case Control
Eligibility
Ages Eligible for Study: 13 Years and above, Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Location and Contact Information
Pennsylvania
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104-4318, United States; Recruiting
More Information
Record last reviewed: December 2003
Last Updated: October 13, 2004
Record first received: January 16, 2001
ClinicalTrials.gov Identifier: NCT00008749
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Autoimmune Diseases (Cleveland Clinic)
- Lupus (Cleveland Clinic)

Not Signed In -

